Hend Ibrahim Shousha

Hend Ibrahim Shousha

Auto-generated profile, based on publicly available information

Hend Ibrahim Shousha

Endemic Medicine and Hepato-gastroenterology Department, Faculty of Medicine, Cairo University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Closed access
JYJu Dong Yang
Ju Dong Yang
EMEssa A Mohamed
Essa A Mohamed
AAAshraf O Abdel Aziz
Ashraf O Abdel Aziz
HSHend I Shousha
Hend I Shousha
MHMohamed B Hashem
Mohamed B Hashem
LRLewis R Roberts
Lewis R Roberts

17 June 2014 in Surgical Endoscopy
Verified
Journal Article
Closed access
PDF file
AAAshraf Abdelaziz
Ashraf Abdelaziz
TETamer Elbaz
Tamer Elbaz
HSHend Ibrahim Shousha
Hend Ibrahim Shousha
SMSherif Mahmoud
Sherif Mahmoud
MIMostafa Ibrahim
Mostafa Ibrahim
MNMohamed Nabeel
Mohamed Nabeel

19 March 2021 in Gut
Verified
Journal Article
Closed access
PDF file
VSVictor Sapena
Victor Sapena
MEMarco Enea
Marco Enea
FTFerran Torres
Ferran Torres
CCCiro Celsa
Ciro Celsa
JRJosé Ríos
José Ríos
MRMaria Reig
Maria Reig
Objective: The benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration. Design: We pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk factors for HCC recurrence were identified using random-effects Poisson. Results: Recurrence rate and death risk per 100PY in DAA-treated patients were 20 (95% CI 13.9 to 29.8, I 2 =74.6%) and 5.7 (2.5 to 15.3, I 2 =54.3), respectively. Predictive factors for recurrence were alpha-fetoprotein logarithm (relative risk (RR)=1.11, 95% CI 1.03 to 1.19; p=0.01, per 1 log of ng/mL), HCC recurrence history pre-DAA initiation (RR=1.11, 95% CI 1.07 to 1.16; p<0.001), performance status (2 vs 0, RR=4.35, 95% CI 1.54 to 11.11; 2 vs 1, RR=3.7, 95% CI 1.3 to 11.11; p=0.01) and tumour burden pre-HCC treatment (multifocal vs solitary nodule, RR=1.75, 95% CI 1.25 to 2.43; p<0.001). No significant difference was observed in RR between the DAA-exposed and DAA-unexposed groups in propensity score-matched patients (RR=0.64, 95% CI 0.37 to 1.1; p=0.1). Conclusion: Effects of DAA exposure on HCC recurrence risk remain inconclusive. Active clinical and radiological follow-up of patients with HCC after HCV eradication with DAA is justified.

1 November 2020 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
SHSomaya Hashem
Somaya Hashem
MEMahmoud ElHefnawi
Mahmoud ElHefnawi
SHShahira Habashy
Shahira Habashy
MEMohamed El-Adawy
Mohamed El-Adawy
GEGamal Esmat
Gamal Esmat
HSHend Ibrahim Shousha
Hend Ibrahim Shousha

1 January 2018 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Closed access
HSHend Ibrahim Shousha
Hend Ibrahim Shousha
AAAbubakr Hussein Awad
Abubakr Hussein Awad
DODalia Abdelhamid Omran
Dalia Abdelhamid Omran
MEMayada Mohamed Elnegouly
Mayada Mohamed Elnegouly
MMMahasen Mabrouk
Mahasen Mabrouk
IL28B single nucleotide polymorphism (rs12979860) is an etiology-independent predictor of hepatitis C virus (HCV)-related hepatic fibrosis. Data mining is a method of predictive analysis which can explore tremendous volumes of information from health records to discover hidden patterns and relationships. The current study aims to evaluate and compare the prediction accuracy of scoring system like aspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 (FIB-4) index versus data mining for the prediction of HCV-related advanced fibrosis. This retrospective study included 427 patients with chronic hepatitis C. We used data mining analysis to construct a decision tree by reduced error (REP) technique, followed by Auto-WEKA tool to select the best classifier out of 39 algorithms to predict advanced fibrosis. APRI and FIB-4 had sensitivity-specificity parameters of 0.523-0.831 and 0.415-0.917, respectively. REPTree algorithm was able to predict advanced fibrosis with sensitivity of 0.749, specificity of 0.729, and receiver operating characteristic (ROC) area of 0.796. Out of the 16 attributes, IL28B genotype was selected by the REPTree as the best predictor for advanced fibrosis. Using Auto-WEKA, the multilayer perceptron (MLP) neural model was selected as the best predictive algorithm with sensitivity of 0.825, specificity of 0.811, and ROC area of 0.880. Thus, MLP is better than APRI, FIB-4, and REPTree for predicting advanced fibrosis for patients with chronic hepatitis C.

15 May 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
AAAshraf Omar Abdelaziz
Ashraf Omar Abdelaziz
TETamer Mahmoud Elbaz
Tamer Mahmoud Elbaz
HSHend Ibrahim Shousha
Hend Ibrahim Shousha
MIMostafa Mohamed Ibrahim
Mostafa Mohamed Ibrahim
MEMostafa Abdel Rahman El-Shazli
Mostafa Abdel Rahman El-Shazli
MNMohamed Mahmoud Nabeel
Mohamed Mahmoud Nabeel
Survival and Prognostic Factors for Hepatocellular Carcinoma: an Egyptian Multidisciplinary Clinic Experience Hepatocellular carcinoma;multidisciplinary;prognosis;survival; Background: Hepatocellular carcinoma (HCC) is a dismal tumor with a high incidence, prevalence and poor prognosis and survival. Management of HCC necessitates multidisciplinary clinics due to the wide heterogeneity in its presentation, different therapeutic options, variable biologic behavior and background presence of chronic liver disease. We studied the different prognostic factors that affected survival of our patients to improve future HCC management and patient survival. Materials and Methods: This study is performed in a specialized multidisciplinary clinic for HCC in Kasr El Eini Hospital, Cairo University, Egypt. We retrospectively analyzed the different patient and tumor characteristics and the primary mode of management applied to our patients. Further analysis was performed using univariate and multivariate statistics. Results: During the period February 2009 till February 2013, 290 HCC patients presented to our multidisciplinary clinic. They were predominantly males and the mean age was $56.5{\pm}7.7years$. All cases developed HCC on top of cirrhosis that was mainly due to HCV (71%). Most of our patients were Child-Pugh A (50%) or B (36.9%) and commonly presented with small single lesions. Transarterial chemoembolization was the most common line of treatment used (32.4%). The overall survival was 79.9% at 6 months, 54.5% at 1 year and 22.4% at 2 years. Serum bilirubin, site of the tumor and type of treatment were the significant independent prognostic factors for survival. Conclusions: Our main prognostic variables are the bilirubin level, the bilobar hepatic affection and the application of specific treatment (either curative or palliative). Multidisciplinary clinics enhance better HCC management.